Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials
Authors' conclusion
The incidence of AKI appears to be stable over time in patients with ARDS enrolled in randomized trials. The development of AKI remains a significant contributing factor to mortality.
Study context
- Population
- Patients with acute respiratory distress syndrome (ARDS) enrolled in 10 multicentre RCTs over 20 years
- Participants
- 5,148 patients · 10 RCTs
- Comparison
- Acute kidney injury (AKI) vs no AKI
- Outcome
- AKI rate and mortality attributable to AKI
Methodological detailsmulticentre, Super Learner ensemble, time-dependent analysis, inverse probability of treatment weighting
- Multicentre
- Super Learner ensemble
- Time-dependent analysis
- Inverse probability of treatment weighting
Pooled result
As reported in the abstract
AKI incidence and attributable mortality
Overall incidence of AKI (n = 2251)
43.7%
Adjusted risk of AKI, ARMA
38.8%
95% CI 35.7 to 41.9%
Adjusted risk of AKI, ROSE
55.8%
95% CI 51.9 to 59.6%
90-day excess mortality attributable to AKI
15.4%
95% CI 12.8 to 17.9%
Further pooled results
Rapid recovery from AKI
- Recovered rapidly from AKI
- 37.1%
- Significantly lower recovery rate in recent trials
- P < 0.001
90-day excess mortality attributable to AKI by trial
- ARMA
- 25.4% (95% CI 18.7 to 32%)
- FACTT
- 11.8% (95% CI 5.5 to 18%)
- Then remained rather stable over time
90-day overall excess mortality attributable to acute kidney disease
- Excess mortality
- 28.4% (95% CI 25.3 to 31.5%)
Original publication
Incidence of acute kidney injury and attributive mortality in acute respiratory distress syndrome randomized trials. Intensive Care Med. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →